Henry Schein Inc (HSIC)
Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.
- Symbol
- HSIC
- Exchange
- Nasdaq
- Sector
- Healthcare
- Industry
- Medical Distribution
- Market cap
- $9.50B
- 52 week range
- 61.95 - 92.18
Valuation
- Share price
- $84.88 (close of 2026-10-02)
- P/E (TTM)
- 24.60x
- Price to book
- 2.49x
- Price to free cash flow
- 16.69x
- Enterprise value
- $13.16B
- Book value per share
- $34.11
Price performance
| Period | Change |
|---|---|
| 1 day | -0.06% |
| 5 days | -1.73% |
| 1 month | -6.10% |
| 3 months | -1.79% |
| 6 months | +14.80% |
| Year to date | +12.30% |
| 1 year | +28.55% |
| 3 years | +15.80% |
| 5 years | +8.09% |
| 10 years | +32.81% |
| All time | +1803.14% |
Members of Congress who disclosed HSIC trades
Gilbert Ray Cisneros · Julie Johnson · Robert Bresnahan
Super investors holding HSIC
Ken Griffin (Citadel) · Richard Pzena (Pzena Investment Management) · David Einhorn (DME Capital Management) · Robert Olstein (Olstein Capital Management) · Ray Dalio (Bridgewater Associates) · Mason Hawkins (Southeastern Asset Management)
Profitability and growth
- Return on equity
- 10.21%
- Return on invested capital
- 7.34%
- Return on assets
- 3.55%
- Return on capital employed
- 8.18%
- Gross margin
- 31.14%
- Net margin
- 3.02%
- EBITDA margin
- 7.31%
- Revenue growth
- 4.03%
- Net income growth
- 2.05%
- Free cash flow growth
- -18.14%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 5.99%
- Current ratio
- 1.32x
- Net debt to EBITDA
- 3.56x
Latest reported year
- Period end
- 2025-12-27
- Fiscal year
- 2025
- Revenue
- $13.18B
- Cost of revenue
- $9.08B
- Gross profit
- $4.11B
- EBITDA
- $964.00M
- Net income
- $398.00M
- Earnings per share
- $3.29
- Interest expense
- $150.00M
- Shares outstanding
- 120.81M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-27 | $13.18B | $4.11B | $398.00M | $3.29 |
| 2024-12-28 | $12.67B | $4.02B | $390.00M | $3.07 |
| 2023-12-30 | $12.34B | $3.86B | $416.00M | $3.18 |
| 2022-12-31 | $12.65B | $3.83B | $538.00M | $3.95 |
| 2021-12-25 | $12.40B | $3.67B | $631.00M | $4.51 |
| 2020-12-26 | $10.12B | $2.82B | $404.00M | $2.83 |
| 2019-12-28 | $9.99B | $3.09B | $694.73M | $4.70 |
| 2018-12-29 | $9.42B | $2.91B | $535.88M | $3.51 |
| 2017-12-30 | $8.88B | $2.75B | $406.30M | $2.59 |
| 2016-12-31 | $11.57B | $3.23B | $506.78M | $3.14 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-27 | 31.14% | 3.02% | 10.21% | 7.34% |
| 2024-12-28 | 31.69% | 3.08% | 9.68% | 7.27% |
| 2023-12-30 | 31.28% | 3.37% | 9.70% | 7.22% |
| 2022-12-31 | 30.29% | 4.25% | 13.14% | 10.54% |
| 2021-12-25 | 29.63% | 5.09% | 15.53% | 12.65% |
| 2020-12-26 | 27.83% | 3.99% | 10.14% | 11.15% |
| 2019-12-28 | 30.95% | 6.96% | 19.14% | 14.72% |
| 2018-12-29 | 30.91% | 5.69% | 15.13% | 11.17% |
| 2017-12-30 | 30.92% | 4.57% | 14.39% | 13.62% |
| 2016-12-31 | 27.88% | 4.38% | 18.09% | 20.22% |
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-27 | $156.00M | - |
| 2024-12-28 | $122.00M | - |
| 2023-12-30 | $171.00M | - |
| 2022-12-31 | $117.00M | $1.05B |
| 2021-12-25 | $118.00M | $822.00M |
| 2020-12-26 | $421.19M | - |
| 2019-12-28 | $106.10M | - |
| 2018-12-29 | $80.21M | - |
| 2017-12-30 | $174.66M | - |
| 2016-12-31 | $62.38M | - |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-27 | $573.00M | $39.00M |
| 2024-12-28 | $700.00M | $39.00M |
| 2023-12-30 | $353.00M | $39.00M |
| 2022-12-31 | $506.00M | $54.00M |
| 2021-12-25 | $631.00M | $78.00M |
| 2020-12-26 | $550.00M | $9.00M |
| 2019-12-28 | $577.87M | $44.92M |
| 2018-12-29 | $613.42M | $32.62M |
| 2017-12-30 | $483.11M | $36.84M |
| 2016-12-31 | $572.40M | $58.25M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-03
- Consensus EPS estimate
- $1.34
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-04 | Jun/2026 | $1.22 |
| 2026-05-05 | Mar/2026 | $1.20 |
| 2026-02-24 | Dec/2025 | $1.30 |
| 2025-11-04 | Sep/2025 | $1.27 |
| 2025-08-05 | Jun/2025 | $1.18 |
| 2025-05-05 | Mar/2025 | $1.11 |
| 2025-02-25 | Dec/2024 | $1.19 |
| 2024-11-05 | Sep/2024 | $1.16 |
Filings and sources
- Company website
- henryschein.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Cardinal Health Inc (CAH) · Cencora, Inc. (COR) · McKesson Corp (MCK) · Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · Alcon Inc (ALC) · Insulet Corp (PODD)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades